NCT01271504View on ClinicalTrials.gov

E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Participants With Hepatocellular Carcinoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

July 19, 2011

Primary Completion Date

June 23, 2015

Study Completion Date

June 23, 2015

Conditions
Hepatocellular Carcinoma
Interventions
DRUG

Sorafenib

Phase Ib: Cohort 1; 200 mg E7050 + 400 mg Sorafenib Cohort 2; 300 mg E7050 + 400 mg Sorafenib Cohort 3; 400 mg E7050 + Sorafenib

DRUG

Sorafenib

"E7050 given orally at 200, 300 or 400 mg once daily.~Sorafenib given orally, 400 mg twice daily."

Trial Locations (24)

1070

Brussels

1200

Brussels

3000

Leuven

20089

Rozzano

27100

Pavia

27599

Chapel Hill

28007

Madrid

28034

Madrid

28046

Madrid

28050

Madrid

33705

St. Petersburg

33905

Fort Myers

37203

Nashville

40124

Modena

43623

Toledo

45267

Cincinnati

49102

Dnipropetrovsk

61037

Kharkiv

79031

Lviv

83092

Donetsk

85715

Tucson

WC1E 6BT

London

M20 4BX

Manchester

G12 OYN

Glasgow

All Listed Sponsors
collaborator

PharmaBio Development Inc.

INDUSTRY

lead

Eisai Inc.

INDUSTRY

NCT01271504 - E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Participants With Hepatocellular Carcinoma | Biotech Hunter | Biotech Hunter